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Edited by Jesus AvilaAbstract Transthyretin (TTR) amyloid ﬁbril formation, which
is triggered by the dissociation of tetrameric TTR, appears to
be the causative factor in familial amyloidotic polyneuropathy
and senile systemic amyloidosis. Binding of thyroxine (T4), a na-
tive ligand of TTR, stabilizes the tetramer, but the bioavailabil-
ity of T4 for TTR binding is limited due to the preferential
binding of T4 to globulin, the major T4 carrier in plasma. Here,
we show that Cr3+ increased the T4-binding capacity of wild-type
(WT) and amyloidogenic V30M-TTR. Moreover, we demon-
strate that Cr3+ and T4 cooperatively suppressed in vitro ﬁbril
formation due to the stabilization of WT-TTR and V30M-TTR.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transthyretin (TTR), which is present in human plasma and
cerebrospinal ﬂuid, is a homotetrameric protein of 55 kDa.
TTR binds and transports thyroxine (T4) and the retinol bind-
ing protein [1]. In certain individuals, TTR is converted into an
insoluble ﬁbrillar structure called amyloid. The precise mecha-
nisms underlying the conversion of TTR into amyloid ﬁbrils
are unknown, but the extensive b-sheet structure of TTR might
be responsible for its amyloidogenic potential [2]. These amy-
loid ﬁbrils putatively cause senile systemic amyloidosis (SSA)
and familial amyloidotic polyneuropathy (FAP) by virtue of
the neurotoxic eﬀects of amyloid or by means of physical inter-
ference with normal organ function [3]. Tetrameric TTR is not
itself amyloidogenic, but dissociation of the tetramer into a
compact non-native monomer with low conformational stabil-
ity can lead to amyloid ﬁbril formation [4]. Several of the 50
FAP-associated TTR single-site mutations have a normal tet-*Corresponding author. Fax: +81 96 371 4405.
E-mail address: hirokai@gpo.kumamoto-u.ac.jp (H. Kai).
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these mutations signiﬁcantly destabilize the tetramer [6,7]. Pre-
venting the conformational changes which initiate amyloid
ﬁbrillization could intervene in the pathogenesis of FAP [8].
Small inhibitor molecules that bind to unoccupied T4-binding
sites of TTR and the halide ions, chloride and iodide, were
shown to enhance tetrameric TTR stability [9,10]. We screened
a number of metal ions that can aﬀect in vitro amyloid forma-
tion and we report here that Cr3+ enhanced the eﬀect of T4 on
the thermostability of both normal- and V30M-TTR tetramers
and suppressed tetramer dissociation induced by low pH.2. Materials and methods
2.1. Puriﬁcation of wild-type TTR and amyloidogenic V30M TTR from
human plasma
Serum wild-type TTR (s-WT-TTR) was puriﬁed as described previ-
ously [11]. Serum amyloidogenic V30M-TTR (s-V30M-TTR) was pre-
pared using fraction IV obtained from human plasma of homozygotic
V30M FAP patients by Cohn’s ethanol fraction method. The subse-
quent puriﬁcation was essentially as described by Ando et al. [11].
2.2. Preparation of recombinant WT-TTR (r-WT-TTR)
Two primers, 5 0-AACATATGGGTCCGACCGGTACCGGTGA-
3 0 and 5 0-AAGTCGACTTATTCTTTCGGGTTGGTAA-3 0, were de-
signed to amplify the wild-type TTR gene by PCR. The PCR product
was digested and ligated into NdeI/SalI pre-digested pET-22b(+) vec-
tor (Novagen, Darmstadt, Germany). The TTR plasmid was used to
transform Escherichia coli strain, BL21(DE3) STAR (Invitrogen,
Carlsbard, CA). Protein expression was induced by isopropyl-b-D-
thiogalactopyranoside (IPTG) for 3 h before harvesting cells. Cell pel-
let was resuspended in 20 mM phosphate buﬀer saline (PBS, pH 7.0),
and lysed by sonication at 4 C. The supernatant was obtained, ﬁltered
and applied onto a DEAE Sepharose Fast Flow column (Amersham).
Bound proteins were eluted with a 20 mM phosphate (pH 7.0)/200 mM
NaCl buﬀer. TTR was further puriﬁed by reverse-phase high-perfor-
mance liquid chromatography (Cosmosil 5C4-AR-300 column, Naca-
lai Tesque, Japan) with an acetonitrile gradient. The fractions
containing TTR were pooled and dialyzed extensively against 20 mM
NH4HCO3 solution, followed by lyophilization. Purity of TTR was
assessed by SDS–PAGE.
2.3. [125I]T4 and
51Cr3+ binding studies
Serum WT-TTR and V30M-TTR having a concentration of 100 lg/
mL in PBS buﬀer were used for T4 and Cr
3+ binding analyses. The con-
centration of [125I]T4 used was 0.6 nM for binding with s-WT-TTR andblished by Elsevier B.V. All rights reserved.
492 T. Sato et al. / FEBS Letters 580 (2006) 491–4966.0 nM for s-V30M-TTR. Binding of [125I]-labeled T4 (1500 lCi/lg,
Amersham Biosciences, NJ) to TTR was carried out at a total volume
of 25 lL at 4 C for 14–18 h in the absence or presence of CrCl3 (300 or
500 lM). Free and protein-bound [125I]T4 were separated using Centri-
Sep columns (Princeton Separations, NJ) and the bound [125I]T4 was
determined using an auto-well gamma counter (ARC-2000, Aloka).
The aﬃnity constants and the number of binding sites were calculated
using Scatchard analysis. For binding assay with Cr3+, 5 lM of
[51Cr]Cl3 (872 lCi/lg, Perkin–Elmer, MA) was incubated with TTR
protein solution in the absence or presence of 360 nM T4, in a manner
as described above. All incubations were done in duplicate.
2.4. Thioﬂavine T-binding assay
Serum or recombinant WT-TTR, or serum V30M-TTR was incu-
bated at 37 C for 5 days in PBS (pH 4.0) with the indicated concen-
tration of Cr3+ and 360 nM to 10 lM T4 or 0 to 10 lM diﬂunisal.
TTR samples were prepared to a ﬁnal concentration of 0.2 mg/mL.
Thioﬂavine T-binding assays were performed on 2.5 lg/mL TTR sam-
ples by adding freshly prepared 10 lM thioﬂavine T to 50 mM glycine
buﬀer (pH 9.0). Fluorescence emission spectra were obtained with exci-
tation and emission wavelengths of 450 and 482 nm, respectively.
Fluorescence measurements were performed with a F-4500 Hitachi
spectroﬂuorometer (Hitachi, Tokyo, Japan).
2.5. High-sensitivity diﬀerential scanning calorimetry
Diﬀerential scanning calorimetry (DSC) was performed with a diﬀer-
ential scanning calorimeter (MC-2, MicroCal, Northhampton, MA)
with cell volumes of 1.22 mL using heating rates of 1 K/min, as de-
scribed previously [12]. TTR samples were prepared at a concentration
of 25 lM in 20 mM sodium phosphate and 150 mM NaCl at the indi-
cated pH in the presence or absence of Cr3+. The data obtained from
DSC were applied to non-linear ﬁtting algorithms to calculate the ther-
modynamic parameters, thermal denaturation temperature (Tm), calo-
rimetric enthalpy (DHcal) and van’t Hoﬀ enthalpy (DHv), from the
temperature dependence of excess molar heat capacity, Cp, by employ-
ing Origine scientiﬁc plotting software (OriginLab Co.).
2.6. Far circular dichroism
Far circular dichroism (CD) was monitored with JASCO J-720 (Ni-
hon Bunko, Tokyo, Japan). Serum WT-TTR samples were incubated
at 37 C for 2 days in PBS buﬀer (pH 4.0) with or without Cr3+
(500 lM). Samples were then analyzed at 25 C using a bandwidth
of 1.0 nm, a time constant of 1 s, a step resolution of 0.5 nm and a scan
speed of 5 nm/min. CD measurements were carried out in triplicate
and spectra were reported as the means of three scans in the range
of 220–240 nm.3. Results
3.1. Eﬀect of Cr3+ on the binding of T4 to serum WT-TTR and
V30M-TTR
It has been shown that binding of the natural ligand T4 sta-
bilizes the tetrameric TTR [13] and that certain metal ions af-Table 1
Summary of scatchard analysis of T4 and Cr
3+ binding in serum TTR
Bound ligands (lM)
T4 binding
WT-TTR 2.16
WT-TTR with Cr3+ (60 lM) 2.37
WT-TTR with Cr3+ (300 lM) 3.06
WT-TTR with Cr3+ (500 lM) 3.97
V30M-TTR 0.29
V30M-TTR with Cr3+ (500 lM) 1.00
Cr3+ binding
WT-TTR 4.00
WT-TTR with T4 (360 nM) 4.17fect amyloidogenesis [14], therefore, we ﬁrst determined the
eﬀect of Cr3+ on T4 binding to TTR. Scatchard analysis of
puriﬁed s-WT-TTR and radiolabeled T4 resulted in a rectilin-
ear curve with a measured aﬃnity (Ka) of 149.5 L/mmol. The
number of binding sites per mol TTR in the eluate was 1.16
(Table 1). Surprisingly, Cr3+ dose-dependently increased the
concentration of bound T4. In the sample containing 500 lM
Cr3+, the bound T4 and the number of binding sites per mol
TTR were approximately twice than that without Cr3+ (Table
1 and Fig. 1A). However, the binding aﬃnity for T4 was dimin-
ished by the addition of Cr3+ (Table 1). We also examined the
eﬀect of Cr3+ on T4-binding to V30M-TTR and found that the
Ka was slightly increased upon the addition of 500 lM Cr
3+.
Moreover, the number of bound T4 per mol V30M-TTR was
increased 3-fold in the presence of Cr3+ (Table 1). These data
suggested that Cr3+ could increase the maximal binding capac-
ity of WT-TTR and V30M-TTR for T4.
We next asked whether Cr3+ itself could possibly bind to
WT-TTR. In Scatchard analysis using puriﬁed s-WT-TTR
and [51Cr3+], we observed that the molar ratio of Cr3+ binding
sites to TTR was 2.16. The presence of T4 had no eﬀect on the
number of bound ligands per mol TTR (Table 1 and Fig. 1B).
However, the Ka was diminished from 1.40 (T4, 0 nM) to 0.60
(T4, 360 nM). These results indicated that Cr
3+ might bind to
WT-TTR and that T4 negatively aﬀects the binding aﬃnity
but not the binding capacity of WT-TTR towards Cr3+.
3.2. Cr3+ and T4 cooperatively suppressed amyloid ﬁbril
formation
To investigate the eﬀect of Cr3+ and T4 on TTR amyloid
ﬁbril formation, we performed thioﬂavine T-binding assay.
It was previously shown that a T4 concentration of more than
10 lM was needed for T4 alone to show a suppressive eﬀect
on amyloid ﬁbril formation of WT-TTR [13]. However,
0.36 lM T4 together with low Cr
3+ concentrations (10–
50 lM) signiﬁcantly suppressed amyloid ﬁbril formation of
s-WT-TTR, when incubated at pH 4.0 for 5 days (Fig. 2A).
Amyloid ﬁbril formation of r-WT-TTR was also suppressed
by Cr3+ in combination with T4 (0.36 lM), albeit at a higher
concentration of Cr3+ (500 lM) (Fig. 2B). To understand the
discrepant eﬀect of Cr3+ on s-WT-TTR and r-WT-TTR, we
determined the level of T4 remaining in the TTR samples
puriﬁed from human plasma used in this study. We found
that s-WT-TTR samples contained 40 nM T4 in bound form
(data not shown). The presence of this natural ligand most
probably contributed to the stabilization of the tetrameric
s-WT-TTR.Bound ligands/tetramer TTR Ka (L/mmol)
1.16 149.5
1.28 105.8
1.65 86.0
2.14 47.2
0.16 18.8
0.54 29.7
2.16 1.40
2.25 0.60
Fig. 1. Binding of T4 to WT-TTR was increased in a Cr
3+
concentration-dependent manner. (A) 100 lg/mL of s-WT-TTR and
0.6 nM [125I]T4 were incubated with or without Cr
3+. Free and protein-
bound [125I]T4 were separated by CentriSep column and bound [
125I]T4
was determined using a gamma counter. The aﬃnity constants and the
number of binding sites were calculated using Scatchard analysis. (B)
100 lg/mL s-WT-TTR and 5 lM [51Cr3+] were incubated with or
without T4 using the method described above. All incubations were
done in duplicate.
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inﬂammatory drugs (NSAIDs), which also bind to TTR as mi-
mic compounds of T4, suppressed amyloid ﬁbril formation
[9,15]. We therefore examined the combined eﬀects of Cr3+
and an NSAID, diﬂunisal, on s-WT-TTR ﬁbril formation. A
concentration higher than 1 lM was needed for diﬂunisal
alone to show suppressive eﬀect on amyloid ﬁbril formation
of s-WT-TTR, but Cr3+ (10 lM) enhanced the eﬀect of diﬂuni-
sal at this concentration when co-incubated at pH 4.0 for 5
days (Fig. 2C).
When we examined the eﬀect of Cr3+ on s-V30M-TTR, we
found that 10 lM Cr3+ in the presence of 0.36 lM T4 was
insuﬃcient in inhibiting ﬁbril formation (Fig. 2D). V30M-
TTR has a very low binding aﬃnity for T4 [16] (Table 1) so
it is possible that higher concentration of T4 might be needed
for suppressing ﬁbril formation. As expected, at 10 lM T4,
ﬂuorescence intensity was reduced by >50% of the control
when Cr3+ was present compared to that without Cr3+
(Fig. 2D). Collectively, our data suggest that Cr3+ and T4 or
diﬂunisal may cooperatively suppress the amyloid ﬁbril forma-
tion of WT- and V30M-TTR.3.3. Eﬀect of Cr3+ on the thermostability of TTR
To evaluate the eﬀect of Cr3+ on the potential conforma-
tional stability of s-WT- and V30M-TTR, we used diﬀerential
scanning calorimetry, which is a useful technique for charac-
terizing the energetics of thermal unfolding of proteins [12].
Cr3+ (500 lM) increased the excess heat capacity, Cp, of s-
WT-TTR at pH 7.4 and concomitantly, an increase in the calo-
rimetric enthalpy was observed, DHcal is 457 kcal mol
1 and
99.6 kcal mol1 with and without Cr3+, respectively (Fig. 3A
and Table 2). WT-TTR at pH 5.0 had a lower thermal dena-
turation than at pH 7.4, but Cr3+ shifted the thermogram to-
wards a higher temperature and almost completely stabilized
WT-TTR incubated at pH 5.0 against heat-related unfolding
(Fig. 3B and Table 2). More importantly, at pH 6.0, the DHcal
of V30M-TTR in the presence of Cr3+ was 2-fold higher than
that without Cr3+ (Table 2). The Cp of V30M-TTR at pH 6.0
was 50% lower than at pH 7.4, but Cr3+ increased the heat
capacity such that at pH 6.0, this sample had the same Cp va-
lue as at pH 7.4 (Fig. 3C), indicating that Cr3+ stabilized the
amyloidogenic V30M-TTR against thermal-induced denatur-
ation. Moreover, the DHv/DHcal ratio of V30M-TTR at pH
6.0 (>1) suggests that aggregation of the denatured form
may occur, but the addition of Cr3+ inhibited its aggregation
(Table 2). Collectively, these data indicated that Cr3+ stabilizes
WT-TTR and V30M-TTR against thermal unfolding at low
pH.
Because certain Cr3+ complexes have been found to induce a
structural transition of human orosomucoid from the native
twisted b-sheet to a more compact a-helix [17], we used circular
dichroic analysis to examine the eﬀect of Cr3+ on the structural
transition of s-WT-TTR. Cr3+ had no eﬀect on the secondary
structure of s-WT-TTR, even at a high concentration (500 lM)
(Fig. 3D). This result suggested that the eﬀect of chromium on
TTR might be mediated through increased T4 binding, not a
direct induction of structural transition of TTR.4. Discussion
Our ﬁndings demonstrate that Cr3+ and T4 cooperatively
suppressed amyloid ﬁbril formation by stabilizing the tetra-
meric structure of WT-TTR and V30M-TTR (Figs. 2 and 3).
A possible mechanism for this observation may be the in-
creased T4 binding to TTR, induced by Cr
3+, as determined
by Scatchard analysis (Fig. 1A and Table 1). Previous studies
demonstrated that the most dramatic reduction of TTR ﬁbril
formation occurs when both T4 binding sites are occupied by
inhibitors that bind to TTR [15]. It is likely that Cr3+, by facil-
itating the binding of T4, contributes to the inhibition of amy-
loid ﬁbril formation. Although we used here CrCl3, we ruled
out the possibility that under the present conditions, Cl itself
suppressed TTR amyloid ﬁbril formation, as reported previ-
ously [18] because in our preliminary screening of metal ions
(Fe3+, Cr3+, Zn2+, Co2+, Cu2+, Cd2+, Mn2+, Ca2+), all the
compounds used were chlorides, but among these, only Cr3+
had a suppressive eﬀect (data not shown). Furthermore, we
used here 500 lM Cl concentration, which is so much lower
than the reported eﬀective Cl concentration (0.5–1.8 M)
[18].
We cannot yet, however, determine exactly how Cr3+ in-
creases TTR binding capacity. It has been reported that
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Fig. 2. Cr3+ and T4 cooperatively suppressed amyloid ﬁbril formation. (A, B) s-WT-TTR or r-WT-TTR was incubated for 5 days at 37 C in PBS
buﬀer (pH 4.0) with the indicated concentration of Cr3+ and 360 nM T4 and analyzed by thioﬂavine T-binding assay. Data shown are representative
of 3 independent experiments. (C) Thioﬂavine T-binding assay was performed on 2.5 lg/mL serum WT-TTR in PBS buﬀer (pH 4.0) with the
indicated concentration of diﬂunisal in the presence or absence of Cr3+. (D) V30M-TTR was incubated for 5 days at 37 C in PBS buﬀer (pH 4.0)
with the indicated concentration of T4 and 10 lM Cr
3+and analyzed by thioﬂavine T-binding assay. Error bars show S.D. of results from three
independent determinations.
494 T. Sato et al. / FEBS Letters 580 (2006) 491–496electrostatic repulsion between two pairs of Lys15 residues in
the TTR destabilized the tetrameric structure and that anion
shielding of these charge repulsions can modulate tetramer sta-
bility and amyloid ﬁbril formation [18]. It is known that T4 can
bind to the two binding sites of TTR but binding of the second
ligand is much weaker than that of the ﬁrst molecule [19]. We
have roughly determined the crystal structure of WT-TTR
with Cr3+ at 1.8 A˚ resolution. Our initial ﬁndings revealed ma-
jor peaks, which may signal the position of Cr3+, next to the
Glu54 residue of TTR on the anomalous diﬀerence Fourier
maps (data not shown). The T4-binding site is topologically
close to Glu54, as crystallographic studies have demonstrated
[20]. Cr3+ may electrostatically neutralize this area and in-
crease the binding of T4 to TTR. Further crystallographic
studies are needed to clarify this hypothesis.Previous reports have shown that tetramer dissociation is the
rate-limiting step for amyloidogenesis in vitro [21], providing a
potential explanation for the observed correlation between the
kinetic and thermodynamic stability of TTR tetramers and
their amyloidogenicity [22]. It is evident from the calorimetric
analyses that Cr3+ eﬀected a change in the heat-induced disso-
ciation pattern of s-WT-TTR at pH 7.4 and endowed heat-tol-
erance to TTR (Fig. 3A). WT-TTR and V30M-TTR, at pH 5.0
and 6.0, respectively were less stable than at pH 7.4, consistent
with previous observations that lower pH renders the tetramer
unstable [23], but Cr3+ stabilized these tetramers against ther-
mal denaturation at low pH (Fig. 3B and C). Ligand binding is
known to give an increment in the thermal stability of a pro-
tein due to an improved structural ordering and compactness
of the protein [24]. It is therefore, possible that Cr3+, having
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Fig. 3. Eﬀect of Cr3+ on the thermostability of TTR. Excess heat capacity of: (A) s-WT-TTR at pH 7.4, (B) s-WT-TTR at pH 5.0 or 7.4, (C) s-V30M-
TTR at pH 6.0 or 7.4, with or without Cr3+, was determined by diﬀerential scanning calorimetry on 25 lM TTR samples and calculated using
Origine scientiﬁc plotting software. (D) The eﬀect of Cr3+ on the secondary structure of s-WT-TTR was examined by far CD. TTR samples were
incubated at 37 C for 2 days in PBS buﬀer (pH 4.0) with or without Cr3+ (500 lM). Far CD was monitored with JASCO J-720. All spectra were
recorded from 220 to 240 nm. Data shown are representative of 3 independent measurements.
Table 2
Thermodynamic parameters of serum WT-TTR and V30M-TTR
Tm DHcal
(kcal/mol)
DHv/DHcal
WT-TTR (pH 7.4) 100.7 99.6 1.21
WT-TTR with Cr3+ (pH 7.4) 102.2 457 0.13
WT-TTR (pH 5.0) 92.8 91.3 0.84
WT-TTR with Cr3+ (pH 5.0) 100.5 101 0.99
V30M-TTR (pH 6.0) 91.7 59.8 2.29
V30M-TTR with Cr3+ (pH 6.0) 92.4 128 0.73
Cr3+ concentration: 500 lM.
T. Sato et al. / FEBS Letters 580 (2006) 491–496 495increased the binding of T4 to TTR would preserve the tetra-
mer integrity and render a higher thermodynamic stability to
TTR, thus, inhibiting amyloid ﬁbril formation. The use of
small molecules to stabilize proteins that easily misfold such
as TTR has been well-documented [9,13,25]. We note here that
Cr3+ can enhance the suppressive eﬀect of 1 lM diﬂunisal on
in vitro ﬁbril formation (Fig. 2C). Our current ﬁndings that
Cr3+, an essential trace element in humans with no known tox-
icity [26], has the potential of stabilizing tetrameric TTR, high-
lights the possible role of ions in TTR stability through
shielding of electrostatic repulsions [18]. It would be interesting
to verify these data in vivo. The present results and similar
studies could contribute to the growing knowledge on the pre-
vention of the onset of amyloidogenesis.Acknowledgments: The authors’ work was supported by grants from
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